India lifts suspension on Natco's generic nanoparticle paclitaxel
This article was originally published in Scrip
Executive Summary
The government of India has stayed the suspension of Natco Pharma's manufacturing (product) licence for its breast cancer drug, Albupax (paclitaxel in an albumin-bound nanoparticle form). Natco says Albupax is the first cut-price generic version of Abraxis BioScience's Abraxane, which is marketed in India by Biocon.